+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

OP0277Effect of Disease Modifying Drugs on Bone Mineral Density in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, and Ankylosing Spondylitis: A Meta-Analysis



OP0277Effect of Disease Modifying Drugs on Bone Mineral Density in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, and Ankylosing Spondylitis: A Meta-Analysis



Annals of the Rheumatic Diseases 73(Suppl 2): 166.2-167




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 064536230

Download citation: RISBibTeXText

DOI: 10.1136/annrheumdis-2014-eular.2540


Related references

Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. Therapeutics and Clinical Risk Management 13: 583-592, 2017

OP0169Association between Use of Disease-Modifying Anti-Rheumatic Drugs and Diabetes in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, or Psoriasis/psoriatic Arthritis: Nationwide, Population-Based Cohort Study of 84,989 Patients: Table 1. Annals of the Rheumatic Diseases 75(Suppl 2): 119.3-120, 2016

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Annals of the Rheumatic Diseases 72(4): 517-524, 2013

SAT0130Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohns disease:. Annals of the Rheumatic Diseases 71(Suppl 3): 514.3-515, 2013

FRI0353Association of Attitudes Toward Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs and Tumor Necrosis Factor Inhibitors and Treatment Adherence in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: Results from the Global Align Study:. Annals of the Rheumatic Diseases 74(Suppl 2): 553.2-554, 2015

The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si. Clinical Rheumatology 38(2): 297-305, 2019

Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis. Patient Preference and Adherence 11: 661-669, 2017

Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. Clinical Rheumatology 37(6): 1617-1623, 2018

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety 15(Sup1): 11-34, 2016

Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety 15(Sup1): 35-54, 2016

Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Journal of Rheumatology 33(11): 2167-2172, 2006

Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. Journal of Medical Economics 16(9): 1120-1128, 2014

AB1163Prevalence of Smoking and Impact on Disease Parameters Among Ankylosing Spondylitis, Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Infliximab or Golimumab. Annals of the Rheumatic Diseases 74(Suppl 2): 1291.3-1292, 2015

Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. Journal of Managed Care and Specialty Pharmacy 23(8): 859-867, 2017

Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis. Clinical and Experimental Rheumatology 27(4 Suppl 55): S159-S163, 2010